Suppression of cell proliferation and regulation of estrogen receptor α signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells

Journal of Endocrinology

Volumn 182, Issue 2, 2004, Pages 325-337

  Chow, Stephanie K Y ^a   Chan, Judy Y W ^a   Fung, Kwok Pui ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ARSENIC TRIOXIDE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; MYC PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL COUNT; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ESTROGEN ACTIVITY; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 4444331077     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1820325     Document Type: Article

References (36)

1. Alarid ET, Bakopoulos N & Solodin N 1999 Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Molecular Endocrinology 13 1522-1534.
2. Berthois Y, Dong XF, Roux-Dossetto M & Martin PM 1990 Expression of estrogen receptor and its messenger ribonucleic acid in the MCF-7 cell line: multiparametric analysis of its processing and regulation by estrogen. Molecular and Cellular Endocrinology 74 11-20.
3. Brunner N, Bronzert D, Vindelov LL, Rygaard K, Spang-Thomsen M & Lippman ME 1989 Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Research 49 1515-1520.
4. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA & Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753-758.
5. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z & Chen GQ 2000 Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14 262-270.
6. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P & Degos L 1990 All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76 1704-1709.
7. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC & Aldaz CM 2000 Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Research 60 5977-5983.
8. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88 1052-1061.
9. Clarke R, Leonessa F, Welch JN & Skaar TC 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacological Reviews 53 25-71.
10. Cullen R, Maguire TM, McDermott EW, Hill ADK, O'Higgins NJ & Duffy MJ 2001 Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer. European Journal of Cancer 37 1118-1122.
11. Dang CV 1999 c-Myc target genes involved in cell growth, apoptosis, and metabolism. Molecular and Cellular Biology 19 1-11.
12. Dickson RB & Lippman ME 1995 Growth factors in breast cancer. Endocrine Reviews 16 559-589.
13. Dubik D & Shiu RP 1988 Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. Journal of Biological Chemistry 263 12705-12708.
14. Dubik D, Dembinski TC & Shiu RP 1987 Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Research 47 6517-6521.
15. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J & Callahan R 1986 Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. PNAS 83 4834-4838.
16. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C & Meltzer PS 2001 Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Research 61 5979-5984.
17. Guo W, Zhu J & Wang H 1999 Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells. Zhonghua XueYeXueZa Zhi 20 453-455.
18. Henderson BE, Ross RK, Pike MC & Casagrande JT 1982 Endogenous hormones as a major factor in human cancer. Cancer Research 42 3232-3239.
19. Henderson BE, Ross R & Bernstein L 1988 Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Research 48 246-253.
20. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ & Wang ZY 1988 Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 567-572.
21. Klinge CM 2000 Estrogen receptor interaction with co-activators and co-repressors. Steroids 65 227-251.
22. Kyprianou N, English HF, Davidson NE & Isaacs JT 1991 Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Research 51 162-166.
23. Lippman M, Bolan G & Huff K 1976 The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Research 36 4595-4601.
24. Mosselman S, Polman J & Dijkema R 1996 ER beta: identificaiton and characterization of a novel human estrogen receptor. FEBS Letters 392 49-53.
25. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL & Leitman DC 2004 Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Research 1 423-428.
26. Pike AC, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li YL, Gustafsson JA & Carlquist M 2001 Structural insights into the mode of action of a pure antiestrogen. Structure 9 145-153.
27. Prall OW, Sarcevic B, Musgrove EA, Watts CK & Sutherland RL 1997 Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. Journal of Biological Chemistry 272 10882-10894.
28. Saceda M, Lippman ME, Chambon P, Lindsey RL, Ponglikitmongkol M, Puente M & Martin MB 1988 Regulation of the estrogen receptor in MCF-7 cells by estradiol. Molecular Endocrinology 2 1157-1162.
29. Salami S & Karami-Tehrani F 2003 Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clinical Biochemistry 36 247-253.
30. Santagati S, Gianazza E, Agrati P, Vegeto E, Patrone C, Pollio G & Maggi A 1997 Oligonucleotides squelching reveals the mechanism of estrogen receptor autologous down-regulation. Molecular Endocrinology 11 938-949.
31. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 3354-3360.
32. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP & Warrell RP Jr 1998 Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine 339 1341-1348.
33. Sutherland RL, Reddel RR & Green MD 1983 Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. European Journal of Cancer and Clinical Oncology 19 307-318.
34. Teixeira C, Reed JC & Pratt MA 1995 Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Research 55 3902-3907.
35. Wang ZY 2001 Arsenic compounds as anticancer agents. Cancer Chemotherapy and Pharmacology 48 (Suppl 1) S72-S76.
36. Warrell RP Jr, de The H, Wang ZY & Degos L 1993 Acute promyelocytic leukemia. New England Journal of Medicine 329 177-189.